[Form 4] Oric Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Oric Pharmaceuticals CFO Dominic Piscitelli executed significant stock sales on June 23-24, 2025, through a pre-planned Rule 10b5-1 trading plan established on December 30, 2024. The transactions included:

• June 23: Sale of 584 shares at $10.00 and 450 shares at $10.01
• June 24: Sale of 32,466 shares at weighted average price of $10.5045 (range $10.34-$10.80)

Following these transactions, Piscitelli's direct ownership decreased from 101,233 to 68,317 shares, representing a roughly 32.5% reduction in his holdings. The sales were executed according to a predetermined trading plan, which helps avoid concerns about insider trading by establishing sale parameters in advance. The transactions demonstrate significant insider selling activity by a key executive officer.

Positive

• The CFO's stock sales were executed according to a pre-planned Rule 10b5-1 trading plan established on December 30, 2024, indicating compliance with insider trading regulations

Negative

• CFO Dominic Piscitelli sold a significant portion (33,500 shares) of his holdings at prices ranging from $10.00 to $10.80, reducing his position by approximately 33% from 101,233 to 68,317 shares
• The substantial reduction in the CFO's equity stake could be interpreted as reduced confidence in the company's near-term prospects

Insights

Insider Trading Specialist

This Form 4 reveals a significant reduction in holdings by CFO Dominic Piscitelli, who sold a total of 33,500 shares (approximately 33% of his position) over two days. The sales were conducted under a 10b5-1 plan established in December 2024, which typically provides some insulation from negative interpretations as these plans must be set up when the insider doesn't possess material non-public information.

However, the magnitude of the selling warrants attention - particularly the larger block of 32,466 shares on June 24th. While planned sales don't necessarily indicate negative outlook, the substantial percentage reduction in holdings (from 101,233 to 68,317 shares) could suggest the CFO is diversifying personal holdings or potentially sees limited near-term upside at current price levels.

Importantly, this transaction occurred at prices around $10-$10.80 per share. Investors should monitor whether other executives follow with similar selling patterns, which would strengthen the signal. For context, I'd want to examine ORIC's recent stock performance and whether this selling comes after any significant price appreciation or ahead of any scheduled clinical or regulatory catalysts.

Biotech Industry Analyst

The CFO's decision to sell approximately 33% of his direct holdings merits consideration within the broader context of ORIC Pharmaceuticals' clinical development timeline. As a clinical-stage oncology company, ORIC's valuation is heavily dependent on pipeline progress rather than current revenue streams.

The sales occurring at the $10-$10.80 range may reflect the CFO's assessment of the company's near-term prospects relative to its current valuation. For biotech companies, executive selling ahead of important data readouts can sometimes signal caution, though the pre-established 10b5-1 plan mitigates this interpretation somewhat.

Given the competitive landscape in precision oncology, where ORIC operates, investors should cross-reference this selling activity with upcoming clinical milestones for the company's lead assets. If major clinical results are expected in Q3-Q4 2025, this selling pattern takes on greater significance. The biotech sector has been particularly volatile in 2024-2025, and executive behavior often provides subtle indicators of confidence in upcoming catalysts that can drive significant valuation changes in clinical-stage companies.

Portfolio Manager

From a portfolio management perspective, this Form 4 filing represents a moderate bearish signal that should be factored into position sizing decisions for ORIC holdings. The CFO's liquidation of one-third of his position, while planned through a 10b5-1 arrangement, still represents a meaningful reduction in skin-in-the-game for a key financial decision maker.

At approximately $10.50 per share, investors should evaluate whether this price point represents fair value given the company's cash position, burn rate, and clinical pipeline potential. The biotech sector often trades on catalyst expectations, and significant insider selling can sometimes precede periods of limited news flow or anticipated disappointments.

I would recommend comparing this selling pattern with historical insider transactions at ORIC and peer companies of similar market capitalization and clinical stage. If this represents an acceleration of selling or diverges from past patterns, it deserves greater weight in investment decisions. For existing shareholders, this might not warrant immediate liquidation but could justify tightening stop-loss levels or reducing position sizes until additional clarity emerges regarding the company's near-term prospects.

Corporate Governance Expert

From a governance perspective, this Form 4 reveals important information about executive confidence and alignment with shareholders. While the CFO retains a substantial position (68,317 shares), the 33% reduction in holdings modifies the alignment of interests between this key executive and outside investors.

The implementation of a 10b5-1 trading plan indicates proper governance protocols are being followed, which is positive. However, the timing and volume of sales warrant monitoring by the board's compensation committee to ensure executive incentives remain appropriately aligned with company performance and shareholder returns.

For investors evaluating ORIC's governance profile, it's worth examining whether other executives or board members have established similar trading plans or executed comparable sales. Multiple insiders reducing positions simultaneously would represent a stronger governance signal than an isolated transaction. Additionally, investors should examine recent proxy statements to determine whether the company has implemented or modified any holding requirements for executives, which could provide context for these sales. The board's responsibility is to ensure executives maintain sufficient equity stakes to drive long-term value creation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Piscitelli Dominic

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/23/2025		S(1)		584	D	$10	101,233	D
Common Stock	06/23/2025		S(1)		450	D	$10.01	100,783	D
Common Stock	06/24/2025		S(1)		32,466	D	$10.5045(2)	68,317	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 30, 2024.

2. Represents the weighted average share price of an aggregate total of 32,466 shares sold in the price range of $10.34 to $10.80 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

	/s/ Christian Kuhlen, attorney-in-fact	06/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many ORIC Pharmaceuticals (ORIC) shares did CFO Dominic Piscitelli sell on June 23-24, 2025?

CFO Dominic Piscitelli sold a total of 33,500 shares of ORIC Pharmaceuticals stock across three transactions: 584 shares at $10.00, 450 shares at $10.01 on June 23, 2025, and 32,466 shares at a weighted average price of $10.5045 on June 24, 2025.

What was the price range of ORIC shares sold by CFO Piscitelli on June 24, 2025?

On June 24, 2025, the 32,466 ORIC shares were sold in the price range of $10.34 to $10.80 per share, with a weighted average sale price of $10.5045.

How many ORIC shares does CFO Piscitelli own after the June 2025 transactions?

Following the reported transactions, CFO Dominic Piscitelli directly owns 68,317 shares of ORIC Pharmaceuticals common stock.

Was ORIC CFO Piscitelli's stock sale part of a pre-planned trading arrangement?

Yes, the sales were executed pursuant to a Rule 10b5-1 trading plan that was adopted by Piscitelli on December 30, 2024.